Day 1 (30 July 2024)
30 July 2024 (Tues) | 08:00 - 16:45
Day 1 Programme
30 Jul | 08:00 - 09:00
Registration and Breakfast
30 Jul | 09:10 - 09:25
Guest of Honour - Opening Address
30 Jul | 09:25 - 10:00
The Value Proposition of Clinical Trials and The Official Launch of Centralised Clinical Trials Portal
"The Value Proposition of Clinical Trials"
CEO, Consortium for Clinical Research and Innovation, Singapore (CRIS)
Executive Director, SCRI
30 Jul | 10:00 - 10:30
Keynote Address 1
"How Clinical Trials Underpinned Our Global Response to the COVID Pandemic"
30 Jul | 10:30 - 11:00
Keynote Address 2
"How Clinical Trials Can Play a Role in Transforming the Singapore Healthcare System"
30 Jul | 11:00 - 11:45
Panel Discussion
"Clinical Trials - Value Proposition from the Patient's, Healthcare and Industry Perspective"
Senior Consultant Medical Oncologist, National University Cancer Institute, Singapore (NCIS)
Associate Professor, NUS Yong Loo Lin School of Medicine
Head, Innovation Transfer Office (Research Office), National University Health System (NUHS)
Mr Adrian Yap
NASH Patient
(Moderator)
CEO, Consortium for Clinical Research and Innovation, Singapore (CRIS)
Executive Director, SCRI
30 Jul | 11:45 - 13:15
Lunch & Networking
30 Jul | 13:15 - 14:45
Track 1: Health Economics and Outcomes Research (HEOR)
"Clinical Trials for Health Outcomes and Its Impact on Healthcare"
Health Economics and Outcomes Research (HEOR) aims to understand the value of healthcare interventions by examining their cost-effectiveness, cost-benefit ratio, and its overall impact on population health. Find out how clinical trials for health outcomes seek to improve the health outcomes of patients, optimise healthcare systems and ensure the cost-efficient use of resources.
Professor & Inaugural Director (2008-2018)
Health Services and Systems Signature Research Programme
Duke-NUS Medical School
Deputy Director, Health Services Research, Changi General Hospital
Deputy Director, Centre for Population Health Research & Implementation, SingHealth
Adjunct Assistant Professor, Duke-NUS Graduate Medical School
Adjunct Senior Fellow, SUTD Academy
Principal Health Economist Chief
Health Economist's Office, Ministry of Health (MOH)
(Moderator)
Director, Cochrane Singapore
Associate Professor, Duke-NUS Medical School
Chief Scientific Officer, SCRI
30 Jul | 13:15 - 14:45
Track 2: Industry Sponsored Track (By Takeda)
"From Theory to Practice, Trials and Tribulations in Singapore"
There are numerous factors influencing clinical trial site selection. In this track, experts from industry,
academia and public health will delve into the suitability of choosing Singapore as a clinical trial site and address some of the unique challenges faced. Using dengue trials as case studies, the session will illustrate
these points and contextualise Singapore's role in the global clinical trial landscape.
Head, NCID Research Office
Consultant, NCID and Tan Tock Seng Hospital
Assistant Professor, Lee Kong Chian School of Medicine
Associate Director and Therapeutic Area Lead
Takeda Development Centre (TDC) Singapore Clinical Operations
Co-Director, Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS AMC
Deputy Clinical and Scientific Director, SingHealth Investigational Medicine Unit
Senior Consultant, Department of Infectious Diseases, Singapore General Hospital
Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School
(Moderator)
Vice Dean (Global Health), Programme Leader (Infectious Diseases) and Professor, NUS Saw Swee Hock School of Public Health (Primary)
Professor, NUS Yong Loo Lin School of Medicine (Joint)
Associate Director, NUS Singapore Centre for Environmental Life Sciences Engineering
Visiting Consultant, St Luke’s Hospital
Visiting Consultant, Ang Mo Kio Community Hospital
Adjunct Clinician-Scientist, NanoBio Lab, A*STAR
30 Jul | 14:45 - 15:15
Tea Break
30 Jul | 15:15 - 16:45
Track 3: Patient Advocacy and Community Engagement
"Patient Advocacy Groups, Community Involvement and Collaboration in Advancing Clinical Research"
Patient advocacy groups and community engagement now play a more significant role in clinical research. Find out how these collaborations encourage a deeper understanding of patient needs, sharpens research relevance, and accelerates the development of innovative therapies for better healthcare.
Vaccines External Engagement Lead, Takeda Pharmaceuticals International
Associate Visiting Expert, Centre of Regulatory Excellence, Duke-NUS Medical School
(Moderator)
Deputy Director, Office of Patient Engagement (OPEN)
Lee Kong Chian School of Medicine, Nanyang Technological University (NTU)
30 Jul | 15:15 - 16:45
Track 4: Decentralised Clinical Trials
"Benefits and Challenges of DCTs"
Decentralised clinical trials have transformed the conduct of clinical trials by offering increased accessibility and flexibility for participants. In this session, hear more on how digital technologies and patient-centric approaches have enhanced patient engagement, reduced physical limitations, and accelerated the progress of decentralised clinical trials.
Executive Director, Cardiovascular Disease National Collaborative Enterprise (CADENCE)
Research Director and Senior Consultant Cardiologist, National Heart Research Institute, National Heart Centre Singapore
Professor (Signature Research Program in Cardiovascular & Metabolic Disorders), Duke-NUS Medical School
30 Jul | 16:45
End of Day 1
*Please note that the programme may be subject to change without prior notice.
Tracks 1-10 will comprise of a 45-min presentation by speakers followed by 45-min panel discussion.